Search PubMed⌕ Search

Biomedical subjects

Dennis P Hanson

Publications and source records attributed to Dennis P Hanson.

2 recordsLinked to original sources

Biomedical image visualization research using the Visible Human Datasets.

The practice of medicine and conduct of research in major segments of the biologic sciences have always relied on visualizations to study the relationship of anatomic structure to biologic function. Traditionally, these visualizations have either been direct, via vivisection and postmortem examination, or have required extensive mental reconstruction. The revolutionary capabilities of 3-D and 4-D medical imaging modalities, together with computer reconstruction and rendering of multidimensional medical and histological volume image data, obviate the need for physical dissection or abstract assembly. The availability of the Visible Human Datasets from the National Library of Medicine, coupled with the development of advanced computer algorithms to accurately and rapidly process, segment, register, measure, and display high resolution 3-D images, has provided a rich opportunity to help advance these important new imaging, visualization, and analysis methodologies from scientific theory to clinical practice.

Algorithms↗

A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS.

The human monoclonal antibody rHIgM22 enhances remyelination following spinal cord demyelination in a virus-induced murine model of multiple sclerosis. Using three-dimensional T2-weighted in vivo spinal cord magnetic resonance imaging (MRI), we have therefore assessed the extent of spinal cord demyelination, before and after 5 weeks of treatment with rHIgM22, to determine whether antibody enhanced remyelination can be detected by MRI. A significant decrease was seen in T2 high signal lesion volume following antibody treatment. Histologic examination of the spinal cord tissue reveals that this decrease in lesion volume correlates with antibody promoted remyelination. To show that rHIgM22 enters the spinal cord and colocalizes with demyelinating lesions, we used ultrasmall superparamagnetic iron oxide particle (USPIO)-labeled antibodies. This may be considered as additional evidence to the hypothesis that rHIgM22 promotes remyelination by local effects in the lesions, likely by binding to CNS cells. The reduction in high signal T2-weighted lesion volume may be an important outcome measure in future clinical trials in humans.

Animals↗